Who Are The Significant Players In the Idefirix Global Market?
Major companies operating in the idefirix market include Hansa Biopharma AB.
What Are the Emerging Trends in The Idefirix Market?
The key trend in the idefirix market is focusing on developing innovative solutions for the desensitization of highly sensitized kidney transplant patients. For instance, in July 2023, Hansa Biopharma announced that the Australian Therapeutic Goods Administration (TGA) approved Idefirix (imlifidase) as a desensitization treatment for highly sensitized kidney transplant patients.
What Are the Market Trends Regionally?
Europe has been the largest market for idefirix in 2024 and is expected to be the fastest-growing region in the forecast period as well. The report covers all major regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Know More About The Idefirix Global Market Report 2025?
The Idefirix Global Market Report 2025 research from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities. Idefirix (imlifidase) is a medication based on enzyme technology designed to reduce donor-specific antibodies enabling successful organ transplantation in highly sensitized kidney transplant patients.